Daniel Haymann’s practice focuses on international and domestic commercial litigation and arbitration as well as corporate and commercial law.
He established the first dedicated cannabis desk at a large law firm in Switzerland and advises investors, start-ups and vertically integrated companies in the cannabis industry along the value chain, including, among others, on regulatory matters (advice includes all regulatory aspects relating to THC, CBD and other cannabinoids; cultivation and distribution, including GMP and GDP standards, as well as retail; EU Novel Food; cosmetics law; medicinal cannabis products under the supervisory authority Swissmedic (as well as Herbal Medicines)).
He gained extensive experience as a commodity trader and in managerial positions in the coal, petroleum coke and fertiliser industries for the two leading international commodity trading firms in their respective fields. He was based in Zurich, Baar, Singapore and Hong Kong. He then joined an International Finance and Business Development Boutique as partner and held management positions in corporate business development.
Rankings & Awards
Education & Admission
- Admitted to the Bar in Switzerland (2019)
- Hong Kong University of Science and Technology, MBA
- University of Zurich, MLaw
Memberships and public offices
- Swiss Bar Association
- Zurich Bar Association
- International Cannabis Bar Association (Member of the International Committee)
- Die Zulässigkeit von Cannabis in kosmetischen Mitteln | 27.06.2022
- Medical Cannabis & Cannabinoid Regulation 2022 Switzerland – Law & Practice and Trends & Developments | 20.06.2022
- Handel mit medizinischem Cannabis: Die Schweiz öffnet sich | 29.05.2022
- Einen Joint to go aus dem Cannabisladen | 07.12.2021
Medical Cannabis & Cannabinoid Regulation 2022 Switzerland – Law & Practice and Trends & DevelopmentsChambers and Partners, Global Practice Guides, Medical Cannabis & Cannabinoid Regulation, 20 June 2022
krautinvest.de, Interview by Moritz Förster, 29. Mai 2022
Interview von Susanne Ziegert mit Daniel Haymann, NZZ am Sonntag, 5. Dezember 2021
Daniel Haymann will be a panelist at the International Cannabis Business Conference (ICBC) Global Investment Forum in Berlin on 18 July 2022 and will moderate a panel at the ICBC B2B tradeshow in Berlin on 19 July 2022
Cannabis Law Institute, Washington DC, 9-11 June 2022
Daniel Haymann – moderator at the CB Expo (Cannabis Business) in Zurich from 11-12 September 2021
Daniel Haymann – Conférencier lors du webinaire « Medical Use of Cannabis in Switzerland » | 20 avril 2021
Daniel Haymann – Keynote Speaker at the Webinar ” Medical Use of Cannabis in Switzerland” | 20 April 2021
Revision: Cannabis Regulation – New Authorization Mechanism for Dealing With Medical Cannabis
On 1 August 2022, not only the annual national holiday could be celebrated extensively in Switzerland. Particularly noteworthy is also the entry into force of the new requirements for the regulation of medical cannabis.
Cannabis was qualified as a prohibited narcotic in Switzerland until the end of summer 2022 – without further specification in relation to a medical application. Accordingly, the cultivation, importation, production, and marketing of cannabis required an exemption permit from the Federal Office of Public Health (FOPH).More
Legal Framework for the Use of Psychedelics in Switzerland
Just in time for summer, the miniseries «How to Change Your Mind» will be launched in July on the Netflix streaming platform. In this documentary series, author Michael Pollan and Co. analyse the history and applications of psychedelic substances such as LSD, psilocybin, MDMA and mescaline. According to experts, research with psychedelics (also known as hallucinogens) or related substances will increase worldwide in the coming years. The market launch of drugs containing MDMA for post-traumatic stress disorder (PTSD) or psilocybin for the treatment of depression is expected in the next five to ten years. The legal framework regarding the use of psychedelics in patients is very pragmatic in Switzerland and unique internationally. Switzerland is a leader in the research and use of psychedelics in psychiatry and is considered an innovation driver in this field. Nevertheless, the regulatory hurdles for researchers and patients are still extremely high. In this article we elaborate on the requirements under which psychedelics may be used in Switzerland today.
LexCast: CBD – Novel Food or Narcotic?
The European Commission recently announced that all CBD Novel Food applications are put on hold while it reviews whether CBD should not be classified as a food, but instead as a narcotic under the United Nations Single Convention on Narcotics of 1961. This re-classification could potentially have wide-ranging and detrimental consequences on a fast-growing industry in Europe.More
LexCast: Shareholder Agreement for Startups: Transfer Restrictions 101
Startups often forget to incorporate appropriate transfer restrictions in their shareholder agreements.More
Ten Questions Every Company Active in the Cannabis Business in Switzerland Should Reflect On
On 26 June 2019, the Federal Council assigned the Federal Department of Home Affairs (FDHA) to conduct a consultation procedure on the amendment of the Federal Narcotics Act (NarcA), which will last until 17 October 2019. The planned amendment to the NarcA aims to facilitate and expand the handling of medicinal cannabis that is exempt from a special approval of the Federal Office of Public Health. In particular, the traffic ban on cannabis narcotics for medicinal purposes is to be lifted, which should lead to limited tradability.More